# A Study to Evaluate the Safety and Effectiveness of Rivaroxaban (Xarelto) for Prevention of Stroke and Systemic Embolism in Indian Patients With Non-valvular Atrial Fibrillation (NVAF)

> **NCT03887780** · — · COMPLETED · sponsor: **Bayer** · enrollment: 504 (actual)

## Conditions studied

- Non-valvular Atrial Fibrillation (NVAF)

## Interventions

- **DRUG:** Rivaroxaban (Xarelto,Bay 59-7939)

## Key facts

- **NCT ID:** NCT03887780
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-03
- **Primary completion:** 2023-12-23
- **Final completion:** 2024-12-16
- **Target enrollment:** 504 (ACTUAL)
- **Last updated:** 2025-01-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03887780

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03887780, "A Study to Evaluate the Safety and Effectiveness of Rivaroxaban (Xarelto) for Prevention of Stroke and Systemic Embolism in Indian Patients With Non-valvular Atrial Fibrillation (NVAF)". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT03887780. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*